Dataset Information


Dose-dependent glycometabolic effects of sotagliflozin on type 1 diabetes over 12?weeks: The inTandem4 trial.



To assess the dose-related effects of sotagliflozin, a novel dual inhibitor of sodium-glucose co-transporters-1 and -2, in type 1 diabetes (T1D).

Materials and methods

In this 12-week, multicentre, randomized, double-blind, placebo-controlled dose-ranging trial, adults with T1D were randomized to once-daily placebo (n = 36) or sotagliflozin 75?mg (n = 35), 200?mg (n = 35) or 400?mg (n = 35). Insulin was maintained at baseline doses. The primary endpoint was least squares mean (LSM) change in glycated haemoglobin (HbA1c) from baseline. Other endpoints included proportion of participants with ?0.5% HbA1c reduction and assessments of 2-hour postprandial glucose (PPG), weight, and urinary glucose excretion (UGE).


From a mean baseline of 8.0%?±?0.8% (full study population), placebo-adjusted LSM HbA1c decreased by 0.3% (P = .07), 0.5% (P?ConclusionsCombined with stable insulin doses, sotagliflozin 200?mg and 400?mg improved glycaemic control and weight in adults with T1D. Sotagliflozin 400?mg reduced PPG levels. UGE increased with all sotagliflozin doses. Rates of severe hypoglycaemia and DKA were low (NCT02459899).

PROVIDER: S-EPMC6851757 | BioStudies |

REPOSITORIES: biostudies

Similar Datasets

| S-EPMC6905498 | BioStudies
| S-EPMC6105319 | BioStudies
| S-EPMC6708262 | BioStudies
| S-EPMC7576419 | BioStudies
| S-EPMC7864092 | BioStudies
| S-EPMC6454301 | BioStudies
| S-EPMC8481733 | BioStudies
| S-EPMC4831906 | BioStudies
| S-EPMC4148334 | BioStudies
| S-EPMC6680204 | BioStudies